Do analysts prefer LIVN or NNNN?

LivaNova currently has a consensus price target of $83.50, indicating a potential upside of 3.96%. Given LivaNova's stronger consensus rating and higher possible upside, equities research analysts plainly believe LivaNova is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score LivaNova 0 Sell rating(s) 5 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.55 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation & earnings, LIVN or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than LivaNova. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LivaNova $1.39B 3.19 -$242.47M $3.38 23.76 Anbio Biotechnology $8.65M 127.59 $6.40M N/A N/A

Do analysts prefer ITGR or NNNN?

Integer presently has a consensus price target of $109.86, indicating a potential downside of 12.32%. Given Integer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Integer is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Integer 0 Sell rating(s) 13 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.07 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, ITGR or NNNN?

Integer has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Integer $1.84B 2.31 $102.81M $3.66 34.23 Anbio Biotechnology $8.65M 127.59 $6.40M N/A N/A

Do analysts recommend IRTC or NNNN?

iRhythm Technologies currently has a consensus target price of $179.93, suggesting a potential upside of 49.63%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe iRhythm Technologies is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score iRhythm Technologies 1 Sell rating(s) 1 Hold rating(s) 12 Buy rating(s) 2 Strong Buy rating(s) 2.94 Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, IRTC or NNNN?

Anbio Biotechnology has lower revenue, but higher earnings than iRhythm Technologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio iRhythm Technologies $747.14M 5.30 -$44.55M -$0.43 N/A Anbio Biotechnology $8.65M 127.59 $6.40M N/A N/A

Do analysts recommend NNNN or PLSE?

Pulse Biosciences has a consensus target price of $45.25, suggesting a potential downside of 4.88%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Pulse Biosciences 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher earnings and valuation, NNNN or PLSE?

Anbio Biotechnology has higher revenue and earnings than Pulse Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 127.59 $6.40M N/A N/A Pulse Biosciences $1.19M 2,778.33 -$72.78M -$1.18 N/A

Do analysts rate NNNN or TMDX?

TransMedics Group has a consensus price target of $124.18, suggesting a potential upside of 40.43%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TransMedics Group 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38

Which has higher earnings & valuation, NNNN or TMDX?

TransMedics Group has higher revenue and earnings than Anbio Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 127.59 $6.40M N/A N/A TransMedics Group $605.49M 5.05 $190.29M $3.89 22.73

Anbio Biotechnology (NNNN) Competitors

$7.67 -0.11 (-1.41%)

As of 08/28/2026 04:00 PM Eastern

Compare

NNNN vs. LIVN, ITGR, IRTC, PLSE, and TMDX

Should you buy Anbio Biotechnology stock or one of its competitors? Anbio Biotechnology's main competitors and comparable companies include LivaNova (LIVN), Integer (ITGR), iRhythm Technologies (IRTC), Pulse Biosciences (PLSE), and TransMedics Group (TMDX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does Anbio Biotechnology compare to LivaNova?

LivaNova (NASDAQ:LIVN) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

97.6% of LivaNova shares are held by institutional investors. 0.4% of LivaNova shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

LivaNova has a net margin of 12.82% compared to Anbio Biotechnology's net margin of 0.00%. LivaNova's return on equity of 16.35% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LivaNova	12.82%	16.35%	7.76%
Anbio Biotechnology	N/A	N/A	N/A

Anbio Biotechnology has lower revenue, but higher earnings than LivaNova.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LivaNova	$1.39B	3.19	-$242.47M	$3.38	23.76
Anbio Biotechnology	$8.65M	127.59	$6.40M	N/A	N/A

LivaNova has a beta of 0.86, indicating that its stock price is 14% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, indicating that its stock price is 440% more volatile than the broader market.

In the previous week, LivaNova had 1 more articles in the media than Anbio Biotechnology. MarketBeat recorded 3 mentions for LivaNova and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.44 beat LivaNova's score of 1.08 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
LivaNova	Positive
Anbio Biotechnology	Positive

LivaNova currently has a consensus price target of $83.50, indicating a potential upside of 3.96%. Given LivaNova's stronger consensus rating and higher possible upside, equities research analysts plainly believe LivaNova is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LivaNova	0 Sell rating(s)	5 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.55
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

LivaNova beats Anbio Biotechnology on 10 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to Integer?

Integer (NYSE:ITGR) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, analyst recommendations, profitability, institutional ownership and valuation.

Integer has a net margin of 6.97% compared to Anbio Biotechnology's net margin of 0.00%. Integer's return on equity of 12.79% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integer	6.97%	12.79%	6.48%
Anbio Biotechnology	N/A	N/A	N/A

Integer has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integer	$1.84B	2.31	$102.81M	$3.66	34.23
Anbio Biotechnology	$8.65M	127.59	$6.40M	N/A	N/A

99.3% of Integer shares are held by institutional investors. 1.1% of Integer shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Integer presently has a consensus price target of $109.86, indicating a potential downside of 12.32%. Given Integer's stronger consensus rating and higher possible upside, equities research analysts clearly believe Integer is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integer	0 Sell rating(s)	13 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.07
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Integer had 21 more articles in the media than Anbio Biotechnology. MarketBeat recorded 23 mentions for Integer and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.44 beat Integer's score of 0.57 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
Integer	Positive
Anbio Biotechnology	Positive

Integer has a beta of 0.61, suggesting that its stock price is 39% less volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, suggesting that its stock price is 440% more volatile than the broader market.

Summary

Integer beats Anbio Biotechnology on 11 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to iRhythm Technologies?

iRhythm Technologies (NASDAQ:IRTC) and Anbio Biotechnology (NASDAQ:NNNN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their valuation, profitability, institutional ownership, risk, earnings, dividends, media sentiment and analyst recommendations.

Anbio Biotechnology has a net margin of 0.00% compared to iRhythm Technologies' net margin of -1.69%. iRhythm Technologies' return on equity of 10.11% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
iRhythm Technologies	-1.69%	10.11%	1.53%
Anbio Biotechnology	N/A	N/A	N/A

iRhythm Technologies currently has a consensus target price of $179.93, suggesting a potential upside of 49.63%. Given iRhythm Technologies' stronger consensus rating and higher possible upside, research analysts clearly believe iRhythm Technologies is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iRhythm Technologies	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	2.94
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

iRhythm Technologies has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market.

In the previous week, iRhythm Technologies had 3 more articles in the media than Anbio Biotechnology. MarketBeat recorded 5 mentions for iRhythm Technologies and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.44 beat iRhythm Technologies' score of 1.08 indicating that Anbio Biotechnology is being referred to more favorably in the news media.

Company	Overall Sentiment
iRhythm Technologies	Positive
Anbio Biotechnology	Positive

Anbio Biotechnology has lower revenue, but higher earnings than iRhythm Technologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iRhythm Technologies	$747.14M	5.30	-$44.55M	-$0.43	N/A
Anbio Biotechnology	$8.65M	127.59	$6.40M	N/A	N/A

Summary

iRhythm Technologies beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Anbio Biotechnology compare to Pulse Biosciences?

Anbio Biotechnology (NASDAQ:NNNN) and Pulse Biosciences (NASDAQ:PLSE) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

In the previous week, Pulse Biosciences had 9 more articles in the media than Anbio Biotechnology. MarketBeat recorded 11 mentions for Pulse Biosciences and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.44 beat Pulse Biosciences' score of 1.14 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
Pulse Biosciences	Positive

76.9% of Pulse Biosciences shares are held by institutional investors. 74.0% of Pulse Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Anbio Biotechnology has a beta of 5.4, suggesting that its share price is 440% more volatile than the broader market. Comparatively, Pulse Biosciences has a beta of 1.61, suggesting that its share price is 61% more volatile than the broader market.

Anbio Biotechnology has a net margin of 0.00% compared to Pulse Biosciences' net margin of -6,755.78%. Anbio Biotechnology's return on equity of 0.00% beat Pulse Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Pulse Biosciences	-6,755.78%	-94.42%	-79.96%

Anbio Biotechnology has higher revenue and earnings than Pulse Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	127.59	$6.40M	N/A	N/A
Pulse Biosciences	$1.19M	2,778.33	-$72.78M	-$1.18	N/A

Pulse Biosciences has a consensus target price of $45.25, suggesting a potential downside of 4.88%. Given Pulse Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Pulse Biosciences is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pulse Biosciences	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Anbio Biotechnology and Pulse Biosciences tied by winning 7 of the 14 factors compared between the two stocks.

How does Anbio Biotechnology compare to TransMedics Group?

Anbio Biotechnology (NASDAQ:NNNN) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

TransMedics Group has a consensus price target of $124.18, suggesting a potential upside of 40.43%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has a net margin of 22.69% compared to Anbio Biotechnology's net margin of 0.00%. TransMedics Group's return on equity of 15.88% beat Anbio Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
TransMedics Group	22.69%	15.88%	5.95%

TransMedics Group has higher revenue and earnings than Anbio Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	127.59	$6.40M	N/A	N/A
TransMedics Group	$605.49M	5.05	$190.29M	$3.89	22.73

Anbio Biotechnology has a beta of 5.4, meaning that its share price is 440% more volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, meaning that its share price is 90% more volatile than the broader market.

In the previous week, TransMedics Group had 7 more articles in the media than Anbio Biotechnology. MarketBeat recorded 9 mentions for TransMedics Group and 2 mentions for Anbio Biotechnology. Anbio Biotechnology's average media sentiment score of 1.44 beat TransMedics Group's score of 1.39 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Positive
TransMedics Group	Positive

Summary

TransMedics Group beats Anbio Biotechnology on 11 of the 14 factors compared between the two stocks.

Get Anbio Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NNNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NNNN vs. The Competition

Export

Metric	Anbio Biotechnology	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.12B	$5.78B	$7.23B	$12.94B
Dividend Yield	N/A	1.75%	2.54%	11.02%
P/E Ratio	N/A	25.92	273.45	25.45
Price / Sales	127.59	44.08	621.81	95.39
Price / Cash	174.81	32.99	79.29	54.21
Price / Book	36.52	6.18	12.97	6.14
Net Income	$6.40M	$149.01M	$3.48B	$348.86M
7 Day Performance	12.63%	-0.24%	0.13%	-0.80%
1 Month Performance	-33.82%	7.85%	8.37%	5.56%
1 Year Performance	N/A	6.22%	24.55%	15.57%

Anbio Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NNNN Anbio Biotechnology	1.214 of 5 stars	$7.67 -1.4%	N/A	N/A	$1.12B	$8.65M	N/A	27	Positive News Short Interest Decrease
LIVN LivaNova	2.4058 of 5 stars	$81.32 +1.8%	$83.50 +2.7%	+44.9%	$4.48B	$1.39B	24.07	3,300	Positive News
ITGR Integer	2.7043 of 5 stars	$125.09 flat	$109.86 -12.2%	+16.8%	$4.25B	$1.85B	34.18	11,000	Positive News Analyst Revision
IRTC iRhythm Technologies	4.2411 of 5 stars	$122.37 +6.2%	$179.93 +47.0%	-29.9%	$4.03B	$747.14M	N/A	2,400	Positive News
PLSE Pulse Biosciences	2.1284 of 5 stars	$48.63 +5.7%	$45.25 -7.0%	+205.7%	$3.37B	$350K	N/A	140	News Coverage Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NNNN) was last updated on 8/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anbio Biotechnology (NNNN) Competitors

NNNN vs. LIVN, ITGR, IRTC, PLSE, and TMDX

How does Anbio Biotechnology compare to LivaNova?

Summary

How does Anbio Biotechnology compare to Integer?

Summary

How does Anbio Biotechnology compare to iRhythm Technologies?

Summary

How does Anbio Biotechnology compare to Pulse Biosciences?

Summary

How does Anbio Biotechnology compare to TransMedics Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anbio Biotechnology (NNNN) Competitors

NNNN vs. LIVN, ITGR, IRTC, PLSE, and TMDX

How does Anbio Biotechnology compare to LivaNova?

Do institutionals & insiders believe in LIVN or NNNN?

Is LIVN or NNNN more profitable?

Which has stronger valuation & earnings, LIVN or NNNN?

Which has more risk and volatility, LIVN or NNNN?

Does the media prefer LIVN or NNNN?

Do analysts prefer LIVN or NNNN?

Summary

How does Anbio Biotechnology compare to Integer?

Is ITGR or NNNN more profitable?

Which has stronger earnings & valuation, ITGR or NNNN?

Do institutionals & insiders have more ownership in ITGR or NNNN?

Do analysts prefer ITGR or NNNN?

Does the media favor ITGR or NNNN?

Which has more volatility and risk, ITGR or NNNN?

Summary

How does Anbio Biotechnology compare to iRhythm Technologies?

Is IRTC or NNNN more profitable?

Do analysts recommend IRTC or NNNN?

Which has more volatility & risk, IRTC or NNNN?

Does the media refer more to IRTC or NNNN?

Which has higher valuation and earnings, IRTC or NNNN?

Summary

How does Anbio Biotechnology compare to Pulse Biosciences?

Does the media prefer NNNN or PLSE?

Do insiders and institutionals believe in NNNN or PLSE?

Which has more volatility and risk, NNNN or PLSE?

Is NNNN or PLSE more profitable?

Which has higher earnings and valuation, NNNN or PLSE?

Do analysts recommend NNNN or PLSE?

Summary

How does Anbio Biotechnology compare to TransMedics Group?

Do insiders & institutionals believe in NNNN or TMDX?

Do analysts rate NNNN or TMDX?

Is NNNN or TMDX more profitable?

Which has higher earnings & valuation, NNNN or TMDX?

Which has more risk and volatility, NNNN or TMDX?

Does the media refer more to NNNN or TMDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NNNN vs. The Competition

Anbio Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools